Reza Mostofi, M.D. Internal Medicine - Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5215 Torrance Blvd, Torrance, CA 90503 Phone: 310-750-1715 Fax: 310-792-6551 |
News Archive
Alitair Pharmaceuticals, Inc., today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its ion exchange resin formulation of benzonatate.
A new automated sample preparation system based on Tecan's Freedom EVO- 200 liquid handling platform has been developed for proteomic biomarker discovery and validation in collaboration with the Translational Genomics Research Institute (TGen) and the Biodesign Institute at Arizona State University.
The Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept. 16-19, 2015.
Though it would seem logical, cancer patients don't always choose therapies with the best chance for survival-cost and side effects are also major considerations. Little has been known about the extent to which cost and side effects influence a patient's treatment decision. Now, new findings by Fox Chase Cancer Center researchers reveals that a patient's socioeconomic status, more than any other characteristic-such as age or disease site-is predictive of whether he or she will favor high efficacy, low cost or low toxicity when choosing a treatment.
› Verified 2 days ago